NGeneBio Co

NGeneBio Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is -77.77. In the previous year, Cash Conversion Cycle (CCC) was 1,062.90 — a change of -107.32% (lower).

Cash Conversion Cycle

-77.77

YoY

-107.32%

Last updated:

Cash Conversion Cycle (CCC) of NGeneBio Co is 2025 -77.77 . Cash Conversion Cycle (CCC) of NGeneBio Co was 2024 1,062.90 . It decreases by -107.32% lower compared to the previous year.

The NGeneBio Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
186.52 KRW
Jan 1, 2019
2,156.72 KRW
Jan 1, 2020
444.04 KRW
Jan 1, 2021
185.02 KRW
Jan 1, 2022
227.08 KRW
Jan 1, 2023
250.43 KRW
Jan 1, 2024
1,062.90 KRW
Jan 1, 2025
-77.77 KRW
The NGeneBio Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-77.77-107.32%
1,062.90+324.43%
250.43+10.28%
227.08+22.73%
185.02-58.33%
444.04-79.41%
2,156.72+1,056.27%
186.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Cash Conversion Cycle (CCC) of NGeneBio Co is -77.77 in 2025.

Cash Conversion Cycle (CCC) of NGeneBio Co changed from 1,062.90 to -77.77, representing a -107.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NGeneBio Co

All Key Metrics — NGeneBio Co